New Delhi: Novawax Inc. on Friday said it has started working on making corona vaccines against variants found in South Africa. It will start testing and manufacturing in the next few weeks. The company's corona shot contains an actual version of the virus's spike protein, which cannot cause disease, but can increase the immune system. The vaccine developer said it has started developing spike proteins, especially based on known genetic sequences of variants. A company spokesperson said, "The arambink work will take a few weeks. ’
Shares of the company closed nearly 9 per cent higher on Friday. Novawax vaccine was allowed to use emergency vaccine for the first time in Indonesia and then in the Philippines early this month. The company has said it will apply for approval from the US by the end of the year. The company has applied for approval in the European Medicines Agency as well as canada. Other vaccine developers, including Germany's Biotech SE and Johnson & Johnson, have reported that they are testing the effectiveness of their shots against the new variant. The new variant has been named Omicron by the World Health Organization.
Inovio Pharmaceuticals Inc. claims:-
Inovio Pharmaceuticals Inc. said it has started trialing its vaccine INO-4800 to evaluate effectiveness against the new variant. The company expects it to take two weeks to trial. Inovio also said that it was designing a new vaccine simultaneously, specifically targeting omicrons. "The best position will be completely effective against ino-4800 omicron," said Kate Brodrick, Senior Vice President, R&D Division, Inovio. If that does not happen, we will have a new designed vaccine if required.